Lack of HLA predominance and HLA shared epitopes in biliary Atresia

Mack, Cara L; Anderson, Kirsten M; Aubrey, Michael T; Rosenthal, Philip; Sokol, Ronald J; Freed, Brian M

doi:10.1186/2193-1801-2-42

SpringerPlus

Table 5 HLA-DR single amino acid polymorphisms**

From: Lack of HLA predominance and HLA shared epitopes in biliary Atresia

Positions^†	Amino acid	Patients (178) n (%)	Controls (684) n (%)	Odds ratio	Pu value*	Pc value*
9	E	103(57.87)	207(30.26)	1.9	0.56	NS
9	K	150(84.27)	291(42.54)	2.0	0.81	NS
10	E	118(66.29)	242(35.38)	1.9	0.29	NS
10	Q	135(75.84)	277(40.50)	1.9	0.17	NS
11	D	32(17.98)	60(8.77)	2.0	0.90	NS
11	G	42(23.60)	77(11.26)	2.1	0.78	NS
11	L	49(27.53)	101(14.77)	1.9	0.63	NS
11	P	54(30.34)	97(14.18)	2.1	0.64	NS
11	S	118(66.29)	242(35.38)	1.9	0.29	NS
12	K	118(66.29)	242(35.38)	1.9	0.29	NS
12	T	138(77.53)	277(40.50)	1.9	0.35	NS
13	F	25(14.04)	53(7.75)	1.8	0.66	NS
13	G	42(23.60)	77(11.26)	2.1	0.78	NS
13	H	42(23.60)	76(11.11)	2.1	0.72	NS
13	R	49(27.53)	101(14.77)	1.9	0.63	NS
13	S	50(28.09)	96(14.04)	2.0	1.00	NS
13	Y	103(57.87)	211(30.85)	1.9	0.40	NS
14	E	42(23.60)	77(11.26)	2.1	0.78	NS
14	K	176(98.88)	338(49.42)	2.0	1.00	NS
16	H	25(14.04)	53(7.75)	1.8	0.66	NS
16	Q	176(98.88)	339(49.56)	2.0	1.00	NS
25	Q	42(23.60)	77(11.26)	2.1	0.78	NS
25	R	176(98.88)	338(49.42)	2.0	1.00	NS
26	F	39(21.91)	76(11.11)	2.0	0.94	NS
26	L	45(25.28)	73(10.67)	2.4	0.31	NS
26	Y	168(94.38)	322(47.08)	2.0	0.92	NS
28	D	82(46.07)	151(22.08)	2.1	0.68	NS
28	E	163(91.57)	315(46.05)	2.0	0.83	NS
30	C	18(10.11)	23(3.36)	3.0	0.17	NS
30	G	32(17.98)	60(8.77)	2.0	0.90	NS
30	H	42(23.60)	77(11.26)	2.1	0.78	NS
30	L	159(89.33)	316(46.20)	1.9	0.24	NS
31	F	39(21.91)	74(10.82)	2.0	0.94	NS
31	I	177(99.44)	339(49.56)	2.0	1.00	NS
32	H	85(47.75)	165(24.12)	2.0	0.92	NS
32	Y	158(88.76)	318(46.49)	1.9	0.10	NS
33	H	50(28.09)	96(14.04)	2.0	1.00	NS
33	N	171(96.07)	330(48.25)	2.0	0.81	NS
37	L	51(28.65)	95(13.89)	2.1	0.83	NS
37	N	75(42.13)	150(21.93)	1.9	0.71	NS
37	S	78(43.82)	147(21.49)	2.0	0.85	NS
37	Y	96(53.93)	185(27.05)	2.0	0.97	NS
38	L	178(100.00)	342(50.00)	2.0	1.00	NS
40	F	178(100.00)	342(50.00)	2.0	1.00	NS
47	F	123(69.10)	243(35.53)	1.9	0.64	NS
47	Y	134(75.28)	273(39.91)	1.9	0.23	NS
57	D	20(11.24)	44(6.43)	1.7	0.59	NS
57	S	58(32.58)	100(14.62)	2.2	0.43	NS
57	V	169(94.94)	322(47.08)	2.0	0.84	NS
58	A	32(17.98)	63(9.21)	2.0	0.90	NS
58	E	175(98.31)	340(49.71)	2.0	0.34	NS
60	S	58(32.58)	100(14.62)	2.2	0.43	NS
60	Y	175(98.31)	333(48.68)	2.0	0.76	NS
67	F	52(29.21)	107(15.64)	1.9	0.63	NS
67	I	114(64.04)	215(31.43)	2.0	0.79	NS
67	L	123(69.10)	223(32.60)	2.1	0.37	NS
70	D	20(11.24)	35(5.12)	2.2	0.72	NS
70	Q	125(70.22)	228(33.33)	2.1	0.41	NS
70	R	130(73.03)	254(37.13)	2.0	0.76	NS
71	A	43(24.16)	89(13.01)	1.9	0.64	NS
71	E	47(26.40)	78(11.40)	2.3	0.36	NS
71	K	58(32.58)	120(17.54)	1.9	0.57	NS
71	R	139(78.09)	264(38.60)	2.0	0.82	NS
73	A	77(43.26)	134(19.59)	2.2	0.37	NS
73	G	170(95.51)	321(46.93)	2.0	0.55	NS
74	E	26(14.61)	48(7.02)	2.1	0.86	NS
74	L	38(21.35)	70(10.23)	2.1	0.81	NS
74	Q	42(23.60)	77(11.26)	2.1	0.78	NS
74	R	153(85.96)	299(43.71)	2.0	0.64	NS
77	N	38(21.35)	71(10.38)	2.1	0.88	NS
77	T	175(98.31)	338(49.42)	2.0	0.70	NS
78	V	49(27.53)	90(13.16)	2.1	0.77	NS
78	Y	176(98.88)	336(49.12)	2.0	0.72	NS
85	V	178(100.00)	341(49.85)	2.0	1.00	NS
86	G	132(74.16)	265(38.74)	1.9	0.40	NS
86	V	133(74.72)	240(35.09)	2.1	0.27	NS

*Pu, uncorrected P values; Pc, corrected P values.
† Polymorphic amino acid positions 9, 10, 11, 12, 13, 14, 16, 25, 26, 28, 30, 31, 32, 33, 37, 38, 40, 47, 57, 58, 60, 67, 70, 71, 73, 74, 77, 78, 85, 86.
** Not displaying amino acid residues that were present in 90% or greater in both patient and control groups, or were present in 10% or fewer in both patient and control groups.

Back to article page